e424b3

Prospectus Supplement No. 2 to
Prospectus dated November 5, 2007
Registration No. 333-127193
Filed pursuant to Rule 424(b)(3)

PROSPECTUS

5,420,022 Shares

REMEDENT, INC.
Common Stock

Supplement No. 2
To
Prospectus Dated November 5, 2007

This Prospectus Supplement No. 2 supplements our Prospectus dated November 5, 2007 and filed with the Securities and Exchange Commission on November 6, 2007, and our Prospectus Supplement No. 1 dated December 11, 2007 and filed with the Securities and Exchange Commission on December 11, 2007, (collectively, the “Prospectus”) relating to the sale of up to 5,420,022 shares of our common stock, $.001 par value, (“Common Stock”) by the Selling Stockholders listed under “Selling Stockholders” on page 35 of the Prospectus filed November 6, 2007. This Prospectus also covers the sale of 4,583,735 shares of our Common Stock by the Selling Stockholders upon the exercise of outstanding warrants. This Prospectus Supplement No. 2 includes the attached Quarterly Report on Form 10-QSB as filed with the Securities and Exchange Commission on February 14, 2008. We will receive gross proceeds of $7,288,138 if all of the warrants are exercised for cash by the Selling Stockholders. We will not receive any proceeds from the sale or other disposition of any common stock by the Selling Stockholders or their transferees. The Prospectus was filed as part of our Registration Statement on Form SB-2, as amended (File No. 333-127193). This Prospectus Supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any amendments or supplements thereto. We encourage you to read this Supplement carefully with the Prospectus.

Our Common Stock is not traded on any national securities exchange or on a NASDAQ Stock Market. Our Common Stock trades on the Over-The-Counter Bulletin Board, under the symbol “REMI.” On April 11, 2008, the last reported closing sale price for our Common Stock was $1.00. There is no public market for the warrants.

INVESTING IN OUR COMMON STOCK INVOLVES CERTAIN RISKS AND UNCERTAINTIES. SEE “RISK FACTORS” BEGINNING ON PAGE 3 OF THE PROSPECTUS DATED NOVEMBER 5, 2007 AND FILED NOVEMBER 6, 2007.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

The date of this Prospectus Supplement is April 14, 2008.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-QSB


þ		QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2007


o		TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-15975

REMEDENT, INC.

(Exact name of small business issuer as specified in its charter)


NEVADA		86-0837251
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification Number)

XAVIER DE COCKLAAN 42, 9831 DEURLE, BELGIUM		N/A

(Address of principal executive offices)		(Zip code)

011 32 9 321 70 80

(Issuer’s telephone number)

Check whether the Issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o Accelerated filer o Non-accelerated filer þ

Number of shares of issuer’s common stock outstanding as of February 12, 2008: 18,606,245

Transitional Small Business Disclosure Format (check one). Yes o No þ

Documents incorporated by reference: None.

PART I — FINANCIAL INFORMATION

Item 1. Interim Condensed Consolidated Financial Statements

REMEDENT, INC. AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2007

(unaudited)

REMEDENT, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS


	December 31, 2007			March 31, 2007
	(unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	2,016,538		$	126,966
Accounts receivable, net of allowance for doubtful accounts of $73,940 at December 31, 2007 and $79,996 at March 31, 2007		1,583,946			1,724,121
Inventories, net		1,128,898			1,132,941
Prepaid expense		1,023,930			668,421

Total current assets		5,753,312			3,652,449

PROPERTY AND EQUIPMENT, NET		727,522			589,623
OTHER ASSETS
Long-term investments and advances		675,000			—
Patents, net		123,974			135,894

TOTAL ASSETS	$	7,279,808		$	4,377,966

LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Current portion, long term debt	$	14,443		$	43,499
Line of Credit		813,344			1,530,276
Notes payable		—			11,282
Accounts payable		1,644,577			1,441,502
Accrued liabilities		377,182			412,435
Due to related parties		50,536			50,536
Taxes payable		81,859			—

Total current liabilities		2,981,941			3,489,530

LONG TERM DEBT		149,715			152,343

STOCKHOLDERS’ EQUITY:
Preferred Stock $0.001 par value (10,000,000 shares authorized, none issued and outstanding)		—			—
Common stock, $0.001 par value; (50,000,000 shares authorized, 18,606,245 shares issued and outstanding at December 31, 2007 and 12,996,245 shares issued and outstanding at March 31, 2007)		18,606			12,996
Additional paid-in capital		17,792,553			11,904,000
Accumulated deficit		(13,640,049	)		(11,147,600	)
Accumulated other comprehensive income (loss) (foreign currency translation adjustment)		(22,958	)		(33,303	)

Total stockholders’ equity		4,148,152			736,093

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	7,279,808		$	4,377,966

COMMITMENTS (Note 18)

The accompanying notes are an integral part of these consolidated financial statements.

REMEDENT, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)


	For the three months ended						For the nine months ended
	December 31,						December 31,
	2007			2006			2007			2006
Net sales	$	2,132,950		$	1,159,408		$	4,453,899		$	4,870,161
Cost of sales		1,271,430			672,050			2,623,506			2,627,724

Gross profit		861,520			487,358			1,830,393			2,242,437

Operating Expenses
Research and development		172,108			63,394			247,665			303,894
Sales and marketing		611,144			119,756			996,937			743,170
General and administrative		1,087,313			872,042			2,891,165			2,543,154
Depreciation and amortization		80,157			59,896			215,941			147,590

TOTAL OPERATING EXPENSES		1,950,722			1,115,088			4,351,708			3,737,808

INCOME (LOSS) FROM OPERATIONS		(1,089,202	)		(627,730	)		(2,521,315	)		(1,495,371	)

OTHER INCOME (EXPENSES)
Interest expense		(16,588	)		(24,849	)		(71,802	)		(122,318	)
Interest income		9,040			—			100,665			—
Other income		—			5,016			—			32,538

TOTAL OTHER INCOME (EXPENSES)		(7,548	)		(19,833	)		28,863			(89,780	)

NET LOSS	$	(1,096,750	)	$	(647,563	)	$	(2,492,452	)	$	(1,585,151	)

LOSS PER SHARE
Basic and fully diluted	$	(0.06	)	$	(0.05	)	$	(0.14	)	$	(0.12	)

WEIGHTED AVERAGE SHARES OUTSTANDING
Basic and fully diluted		18,602,115			12,996,245			17,557,700			12,963,794

The accompanying notes are an integral part of these consolidated financial statements.

REMEDENT, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)


	For the nine months ended
	December 31,
	2007			2006
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(2,492,452	)	$	(1,585,151	)
Adjustments to reconcile net loss to net cash used by operating activities
Depreciation and amortization		215,941			147,590
Allowance for doubtful accounts		(13,417	)		(2,597	)
Stock issued upon conversion of convertible debentures		—			25,706
Value of stock options to employees and consultants		101,271			221,959
Changes in operating assets and liabilities:
Accounts receivable		137,273			990,234
Inventories		4,043			373,479
Prepaid expenses		(352,607	)		(357,197	)
Accounts payable		203,075			(366,123	)
Accrued liabilities		(35,253	)		(177,609	)
Income taxes payable		81,859			(107,783	)

Net cash used by operating activities		(2,150,267	)		(837,492	)

CASH FLOWS FROM INVESTING ACTIVITIES
Decrease (increase) in restricted cash		—			70,762
Long-term investments		(675,000	)		—
Purchases of patents		(11,998	)		—
Purchases of equipment		(165,195	)		(356,336	)

Net cash used by investing activities		(852,193	)		(285,574	)

CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from issuance of stock		5,792,893			—
Principal payments on (proceeds from) capital lease note payable		(31,684	)		121,203
Note payments — related parties		—			(8,422	)
Proceeds from (repayments of) line of credit		(716,932	)		1,024,679

Net cash provided by financing activities		5,044,277			1,137,460

NET INCREASE IN CASH		2,041,817			14,394
Effect of exchange rate changes on cash and cash equivalents		(152,245	)		(61,325	)
CASH AND CASH EQUIVALENTS, BEGINNING		126,966			332,145

CASH AND CASH EQUIVALENTS, ENDING	$	2,016,538		$	285,214

Supplemental Information:
Interest paid	$	14,418		$	76,377

Income taxes paid	$	—		$	—

The accompanying notes are an integral part of these consolidated financial statements.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2007
(unaudited)

1. BACKGROUND AND ORGANIZATION

The Company is a manufacturer and distributor of cosmetic dentistry products, including a full line of professional dental and retail “Over-The-Counter” tooth whitening products which are distributed in Europe, and recently in Asia and the United States. The Company manufactures many of its products in its facility in Deurle, Belgium as well as outsourced manufacturing in China. The Company distributes its products using both its own internal sales force and through the use of third party distributors.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization and Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Remedent, Inc. (formerly Remedent USA, Inc.), a Nevada corporation, and its four subsidiaries, Remedent N.V. (Belgian corporation) located in Deurle, Belgium, Remedent Professional, Inc. (incorporated in California) and a subsidiary of Remedent Professional Holdings, Inc., Remedent Asia Pte. Ltd, a wholly-owned subsidiary formed under the laws of Singapore, and Sylphar N.V. (incorporated in Belgium as a wholly owned subsidiary on September 24, 2007), (collectively, the “Company”). Remedent, Inc. is a holding company with headquarters in Deurle, Belgium. Remedent Professional, Inc. and Remedent Professional Holdings, Inc. have been dormant since inception. Remedent Asia Pte. Ltd., commenced operations as of July 2005. All significant inter-company accounts and transactions have been eliminated in the consolidated financial statements. Corporate administrative costs are not allocated to subsidiaries.

Interim Financial Information

The interim consolidated financial statements of Remedent, Inc. and Subsidiaries (the “Company”) are condensed and do not include some of the information necessary to obtain a complete understanding of the financial data. Management believes that all adjustments necessary for a fair presentation of results have been included in the unaudited consolidated financial statements for the interim periods presented. Operating results for the nine months ended December 31, 2007, are not necessarily indicative of the results that may be expected for the year ended March 31, 2008. Accordingly, your attention is directed to footnote disclosures found in the Annual Report on Form 10-KSB for the year ended March 31, 2007, and particularly to Note 1, which includes a summary of significant accounting policies.

Basis of Presentation

The Company’s financial statements have been prepared on an accrual basis of accounting, in conformity with accounting principles generally accepted in the United States of America. These principles contemplate the realization of assets and liquidation of liabilities in the normal course of business. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Revenue Recognition

The Company recognizes revenue from product sales when persuasive evidence of a sale exists: that is, a product is shipped under an agreement with a customer; risk of loss and title has passed to the customer; the fee is fixed or determinable; and collection of the resulting receivable is reasonably assured. Sales allowances are estimated based upon historical experience of sales returns.

Pervasiveness of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during

the reporting period. On an on-going basis, the Company evaluates estimates and judgments, including those related to revenue, bad debts, inventories, fixed assets, intangible assets, stock based compensation, income taxes, and contingencies. Estimates are based on historical experience and on various other assumptions that the Company believes reasonable in the circumstances. The results form the basis for making judgments about the carrying vales of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

Adoption of New Accounting Policies

Effective January 1, 2007, the Company adopted the provisions of the FASB Staff Position (“FSP”)on EITF Issue 00-19-2 “Accounting for Registration Payment Arrangements”. This accounting position was adopted on a prospective basis with no restatement of prior period consolidated financial statements. This position specifies that the contingent obligation to make future payments or otherwise transfer consideration under a registration payment arrangement, whether issued as a separate agreement or included as a provision of a financial instrument or other agreement, should be separately recognized and measured in accordance with FASB Statement No. 5 “Accounting for Contingencies”. Transition to the FSP will be achieved by reporting a change in accounting principle through a cumulative-effect adjustment to the opening balance of deficit.

The Company adopted FASB Interpretation No.48, “Accounting for Uncertainty in Income Taxes, an interpretation of FASB Statements No. 109” (“FIN 48”) on January 1, 2007. FIN 48 clarifies the accounting for uncertainty in income taxes by prescribing a two-step method of first evaluating whether a tax position has met a more likely than not recognition threshold and second, measuring that tax position to determine the amount of benefit to be recognized in the financial statements. FIN 48 provides guidance on the presentation of such positions within a classified statement of financial position as well as on derecognition, interest and penalties, accounting in interim periods, disclosure, and transition. The adoption of this statement did result in a cumulative adjustment to equity and there were no unrecognized tax benefits, penalties or interest at the time of, or subsequent to, adoption.

Recent Accounting Pronouncements

In December 2007, the FASB issued SFAS No. 141 (Revised) “Business Combinations”. SFAS 141 (Revised) establishes principles and requirements for how the acquirer of a business recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree. The statement also provides guidance for recognizing and measuring the goodwill acquired in the business combination and determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. The guidance will become effective for the Company’s fiscal year beginning April 1, 2009. Management is in the process of evaluating the impact SFAS 141 (Revised) will have on the Company’s financial statements upon adoption.

In December 2007, the FASB issued SFAS No. 160 “Noncontrolling Interests in Consolidated Financial Statements — an amendment of ARB No. 51”. SFAS 160 establishes accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. The guidance will become effective for the Company’s fiscal year beginning April 1, 2009. Management is in the process of evaluating the impact SFAS 160 will have on the Company’s financial statements upon adoption.

In February 2007, the Financial Accounting Standards Board (FASB) issued SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities — Including an Amendment of FASB Statement No. 115”. This statement permits entities to choose to measure many financial instruments and certain other items at fair value. Most of the provisions of SFAS No. 159 apply only to entities that elect the fair value option. However, the amendment to SFAS No. 115 “Accounting for Certain Investments in Debt and Equity Securities” applies to all entities with available-for-sale and trading securities. SFAS No. 159 is effective for the Company ‘s fiscal year beginning April 1, 2008. The adoption of this statement is not expected to have a material effect on the Company’s financial statements.

In September 2006, FASB issued SFAS No. 157, “Fair Value Measurements” (“SFAS 157”). The objective of SFAS 157 is to increase consistency and comparability in fair value measurements and to expand disclosures about fair value measurements. SFAS 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. SFAS 157 applies under other accounting pronouncements that require or permit fair value measurements and does not require any new fair value measurements. The provisions of SFAS 157 are effective for fair value measurements made in the Company’s fiscal years beginning April 1, 2008. The Company has not determined the effect, if any, that the adoption of SFAS 157 will have on the Company’s consolidated financial position or results of operations.

3. PRIVATE PLACEMENT

On June 25, 2007, the Company completed its private offering of 5,600,000 shares of its common stock, par value $.001 per share at a purchase price of $1.25 per share (the “Shares”) and warrants to purchase 4,200,000 shares of common stock, par value $.001 per share, at an exercise price of $1.55 per share (the “Warrants”) to certain institutional and accredited investors, for an aggregate purchase price of $7,000,000 (the “Offering”).

Under the terms of the Offering, the Warrants are exercisable for a period of five years and entitle the holder to purchase one share of restricted common stock (the “Warrant Shares”) for $1.55 per Warrant Share. The Company also has the right to redeem the Warrants for $0.001 per Warrant Share covered by the Warrants if the Shares trade on the OTC Electronic Bulletin Board or similar market above $5.25 per share for 20 consecutive trading days following the initial effective date of the registration statement covering the resale of the Shares and Warrant Shares, based upon the closing bid price for the Shares for each trading day (the “Redemption Right”). Once the Redemption Right vests, the Company has the right, but not the obligation, to redeem the Warrants for $0.001 per Warrant Share covered by the Warrants upon 30 days written notice to the holders of the Warrants.

Under the terms of the Purchase Agreement and the Registration Rights Agreement, the Company was required to prepare and file with the Securities and Exchange Commission (the “Commission”) a registration statement covering the resale of the Shares and the Warrant Shares. The Company agreed to prepare and file a registration statement covering the resale no later than 30 days after the Closing. The registration statement became effective October 23, 2007.

The Company engaged Roth Capital Partners, LLC, as its exclusive agent to offer the Shares and Warrants (the “Placement Agent”). The Placement Agent is entitled to a fee equal to ten percent (10%) of the gross proceeds derived from the Offering, of which the Placement Agent may, at its option, receive up to 2% of its 10% fee in securities issued in the Offering. Further, the Company agreed to pay the Placement Agent 5% of the exercise price of the Warrants promptly following the Company’s receipt thereof. In addition, the Company agreed to reimburse the Placement Agent for its out-of-pocket expenses related to the Offering, including an up front payment of $25,000 to cover such expenses, of which any unused amount will be netted against the Placement Agent’s 10% fee.

As of December 31, 2007, the total costs of this private placement were $1,223,007, comprising of: commissions of $762,505; out-of-pocket costs of $25,000; professional fees of $363,522 and direct travel costs of $71,980; and have been recorded against share capital as a cost of financing.

The Offering was conducted in reliance upon an exemption from registration under the Securities Act of 1933, as amended (the “Securities Act”), including, without limitation, that under Section 506 of Regulation D promulgated under the Securities Act. The Units were offered and sold by the Company to accredited investors in reliance on Section 506 of Regulation D of the Securities Act of 1933, as amended.

4. CONCENTRATION OF RISK

Financial Instruments — Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of trade accounts receivable.

Concentrations of credit risk with respect to trade receivables are normally limited due to the number of customers comprising the Company’s customer base and their dispersion across different geographic areas. At December 31, 2007 one customer accounted for 21.81% of the Company’s trade accounts receivable compared to two customers at December 31, 2006 who accounted for 28% and 16.7% of accounts receivable respectively. The Company performs ongoing credit evaluations of its customers and normally does not require collateral to support accounts receivable.

Purchases — The Company has diversified its sources for product components and finished goods and, as a result, the loss of a supplier would not have a material impact on the Company’s operations. For the nine month period ended December 31, 2007, the Company had five suppliers who accounted for a total of 14.13% of gross purchases. For the nine month period ended December 31, 2006, the Company relied on two factories to manufacture certain components of its new MetaTray and iWhite products which represented 32 % of the Company’s purchases.

		Revenues — For the nine month period ended December 31, 2007 the Company had five customers that accounted for 34.20% of total revenues. For the nine months ended December 31, 2006 the Company had one customer that accounted for 41,8 % of total revenues.

5.		ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

		A summary of accounts receivable and allowance for doubtful accounts as of December 31, 2007 and March 31, 2007 is as follows:


	December 31, 2007			March 31, 2007
Accounts receivable, gross	$	1,657,886		$	1,804,117
Less: allowance for doubtful accounts		(73,940	)		(79,996	)

Accounts receivable, net	$	1,583,946		$	1,724,121

6.		INVENTORIES

		Inventories are stated at the lower of cost (weighted average) or market. Inventory costs include material, labor and manufacturing overhead. Individual components of inventory are listed below as follows:


	December 31, 2007			March 31, 2007
Raw materials	$	34,660		$	30,579
Components		902,181			786,728
Finished goods		206,779			329,000

		1,143,620			1,146,307
Less: reserve for obsolescence		(14,722	)		(13,366	)

Net inventory	$	1,128,898		$	1,132,941

7.		PREPAID EXPENSES

		Prepaid expenses are summarized as follows:


	December 31, 2007		March 31, 2007
Prepaid materials and components	$	518,193	$	394,598
Prepaid Belgium income taxes		73,605		66,830
Prepaid consulting		98,540		66,830
VAT payments in excess of VAT receipts		196,388		47,260
Royalties		36,803		33,415
Prepaid trade show expenses		45,526		6,523
Prepaid rent		10,066		7,054
Other		44,809		45,911

	$	1,023,930	$	668,421

8.		PROPERTY AND EQUIPMENT

		Property and equipment are summarized as follows:


	December 31, 2007			March 31, 2007
Furniture and Fixtures	$	180,603		$	137,560
Machinery and Equipment		768,971			559,422
Tooling		254,450			188,450

		1,204,024			885,432
Accumulated depreciation		(476,502	)		(295,809	)

Property & equipment, net	$	727,522		$	589,623

Tooling includes a payment made to a company called Sensable, in reference to the development of a tailored veneer modeling solution, referred to as “GlamSmile Design Software”. At the end of December 31, 2007, named software was still under development and is expected to be delivered to the company by the end of next quarter, beginning of the following quarter.

9.		LONG TERM INVESTMENTS AND ADVANCES

		Innovative Medical & Dental Solutions, LLC (“IMDS, LLC”)

		Effective July 15, 2007 the Company entered into a Limited Liability Company Merger and Equity Reallocation Agreement (the “Participation Agreement”) through its subsidiary, Remedent N.V. Pursuant to the terms of the Participation Agreement, the Company has acquired a 10% equity interest in IMDS, LLC in consideration for $300,000 which was converted against IMDS receivables.

		The agreement stipulates certain exclusive world wide rights to certain tooth whitening technology, and the right to purchase at standard cost certain whitening lights and accessories and to sell such lights in markets not served by the LLC. The terms of the Participation Agreement also provide that Remedent N.V. has the first right to purchase additional equity. Parties to the Participation Agreement include two officers of IMDS, LLC, and an individual who is both an officer and director of Remedent Inc., and certain unrelated parties.

		IMDS, LLC is registered with the Secretary of the State of Florida as a limited liability company and with the Secretary of the State of California as a foreign corporation authorized to operate in California. IMDS, LLC is merging with White Science World Wide, LLC, a limited liability company organized under the laws of the State of Georgia. The merged companies will operate as a single entity as IMDS, LLC, a Florida limited liability company.

		Soca Networks Singapore (“Soca”)

		Pursuant to the terms of a letter of intent dated December 17, 2007, the Company has agreed to purchase 20% of Soca for a total purchase price of $750,000. Half of the purchase price has been advanced $375,000 to Soca as a down payment, pending completion of the agreement terms. The balance of $375,000 is to be paid through the issuance of 220,588 shares of the Company’s common stock. The final agreement is currently being negotiated and management expects to close the agreement prior to year end.

10.		LICENSED PATENTS

		Teeth Whitening Patents

		In October 2004, the Company acquired from the inventor the exclusive, perpetual license to two issued United States patents which are applicable to several teeth whitening products currently being marketed by the Company. Pursuant to the terms of the license agreement, the Company was granted an exclusive, worldwide, perpetual license to manufacture, market, distribute and sell the products contemplated by the patents subject to the payment of $65,000 as reimbursement to the patent holder for legal and other costs associated with obtaining the patents, which was paid in October 2004, and royalties for each unit sold subject to an annual minimum royalty of $100,000 per year. The Company is amortizing the initial cost of $65,000 for these patents over a ten year period and accordingly has recorded $21,125 of accumulated amortization for this patent as of December 31, 2007. The Company accrues this royalty when it becomes payable to the inventory therefore no provision has been made for this obligation as of December 31, 2007.

		Universal Applicator Patent

		In September 2004, the Company entered into an agreement with Lident N.V. (“Lident”), a company controlled by Mr. De Vreese, the Company’s Chairman, to obtain an option, exercisable through December 31, 2005, to license an international patent (excluding the US) and worldwide manufacturing and distribution rights for a potential new product which Lident had been assigned certain rights by the inventors of the products, who are unrelated parties, prior to Mr. De Vreese association with the Company. The patent is an Italian patent which relates to a single use universal applicator for dental pastes, salves, creams, powders, liquids and other substances where manual application could be relevant. The Company has filed to have the patent approved throughout Europe. The agreement required the Company to advance to the inventors through Lident a fully refundable deposit of €100,000 subject to the Company’s due diligence regarding the enforceability of the patent and marketability of the product, which, if viable, would be assigned to the Company for additional consideration to the inventors of €100,000 and an ongoing royalty from sales of products related to the patent equal to 3% of net sales and, if not viable, the deposit would be repaid in full by Lident. The consideration the Company had agreed to pay Lident upon the exercise of the option is the same as the consideration Lident is obligated to pay the original inventors. Consequently, Lident would not have profited from the exercise of

		the option. Furthermore, at a meeting of the Company’s Board of Directors on July 13, 2005, the Board accepted Lident’s offer to facilitate an assignment of Lident’s intellectual property rights to the technology to the Company in exchange for the reimbursement of Lident’s actual costs incurred relating to the intellectual property. Consequently, when the Company exercises the option, all future payments, other than the reimbursement of costs would be paid directly to the original inventors and not to Lident.

		On December 12, 2005, the Company exercised the option and the Company and the patent holder agreed to revise the assignment agreement whereby the Company agreed to pay €50,000 additional compensation in the form of prepaid royalties instead of the €100,000 previously agreed, €25,000 of which had been paid by the Company in September 2005 and the remaining €25,000 to be paid upon the Company’s first shipment of a product covered by the patent. The patent is being amortized over five (5) years and accordingly, the Company has recorded $50,297 of accumulated amortization for this patent as of December 31, 2007. At the end of December 31, 2007, the product has not yet been commercialized. Management believes no impairment is applicable.

11.		LINE OF CREDIT

		On October 8, 2004, our wholly owned subsidiary, Remedent N.V., obtained a mixed-use line of credit facility with Fortis Bank, a Belgian bank, for €1,070,000 (the “Facility”). The Facility was secured by a first lien on the assets of Remedent N.V. The purpose of the Facility is to provide working capital to grow our business and to finance certain accounts receivable as necessary. Since opening the Facility in 2004, Remedent N.V. and Fortis Bank have subsequently amended the Facility several times to increase or decrease the line of credit. On May 3, 2005 the Facility was amended to decrease the line of credit to €1,050,000. On March 13, 2006 the Facility was amended to increase the mixed-use line of credit to €2,300,000, consisting of a €1,800,000 credit line based on the eligible accounts receivable and a €500,000 general line of credit. The latest amendment to the Facility, dated September 1, 2006, amended and decreased the mixed-use line of credit to €2,050,000. Each line of credit carries its own interest rates and fees as provided in the Facility. Remedent N.V. is currently only utilizing two lines of credit, advances based on account receivables and the straight loan. As of December 31, 2007 and March 31, 2007, Remedent N.V. had, in the aggregate, $813,344 and $1,530,276 advances outstanding, respectively, under this mixed-use line of credit facility.

12.		LONG TERM DEBT

		On September 15, 2005, the Company entered into two five year capital lease agreements for manufacturing equipment totaling €70,296 (US $85,231). On October 24, 2006, the Company entered into another five year capital lease agreement for additional manufacturing equipment totaling €123,367 (US $157,503). The leases require monthly payments of principal and interest at 7.43% of €1,258 (US$1,852 at December 31, 2007) for the first two leases and 9.72% of €2,256 (US$3,321 at December 31, 2007) and provide for buyouts at the conclusion of the five year term of €2,820 (US$4,151) or 4.0% of original value for the first two contracts and €4,933 (US $7,262) or 4.0 % of the original value for the second contract. The book value as of December 31, 2007 and March 31, 2007 of the equipment subject to the foregoing leases are $161,811 and $198,225, respectively.

13.		DUE TO RELATED PARTIES AND RELATED PARTY TRANSACTIONS

		Balances due to related parties consist of the following:


	December 31, 2007		March 31, 2007
Demand loan from a former officer and major stockholder	$	50,536	$	50,536

	$	50,536	$	50,536

		Borrowings from employees and entities controlled by officers of the Company are, unsecured, non-interest bearing, and due on demand.

		Transactions with related parties consisted of the following:

		Compensation:

		During the nine month periods ended December 31, 2007 and 2006 respectively, the Company incurred $483,304 and $441,707 respectively, as compensation for all directors and officers.

		Effective August 8, 2007, the Company appointed a Senior Vice President and Head of U.S. Marketing. Terms of the appointment provide for an initial base salary of $150,000 per year and options to purchase 100,000 shares of common stock under the Company’s 2004 Incentive and Nonstatutory Stock Option Plan (granted — Refer to Note 16).

		Sales Transactions:

		One of the Company’s directors owns a 5% interest in a client company, IMDS Inc. (refer to Note 9), to which goods were sold during the years ended March 31, 2007 and 2006 totaling $476,122 and $38,494 respectively, sales during the three month period ended December 31, 2007 totaled $ 47,256. Accounts receivable with this customer totaled $63,272 and $ 105,851 as at December 31, 2007 and 2006 respectively.

		All related party transactions involving provision of services or tangible assets were recorded at the exchange amount, which is the value established and agreed to by the related parties reflecting arms length consideration payable for similar services or transfers.

		Other related party transactions are disclosed in Supplemental Non-Cash Investing and Financing Activities, clause (e), and Note 17. (Refer to Note 9.)

14.		ACCRUED LIABILITIES

		Accrued liabilities are summarized as follows:


	December 31, 2007		March 31, 2007
Accrued customer prepayments	$	12,401	$	—
Accrued payroll and employee benefit taxes		167,234		260,676
Commissions		4,291		2,834
Accrued audit and tax preparation fees		19,000		27,282
Reserve for warranty costs		22,082		20,049
Accrued interest		1,289		6,180
Accrued consulting fees		11,701		2,528
Other accrued expenses		139,183		92,886

	$	377,182	$	412,435

15.		CAPITAL STOCK

		During the three months ended December 31, 2007 the Company received $15,900 on the exercise of 10,000 common stock purchase warrants.

16.		EQUITY COMPENSATION PLANS

		The Board of Directors and stockholders approved the Nonstatutory Stock Option Plan (the “2001 Plan”) and adopted it on May 29, 2001. The Company has reserved 250,000 shares of its common stock for issuance to the directors, employees and consultants under the Plan. The Plan is administered by the Board of Directors. Vesting terms of the options range from immediately to five years.

		Pursuant to an Information Statement on Schedule 14C mailed on May 9, 2005 to all stockholders of record as of the close of business on February 1, 2005 and became effective September 3, 2005, the Company authorized the implementation of a 2004 Incentive and Nonstatutory Stock Option Plan (“2004 Plan”) reserving 800,000 shares of common stock for issuance to employees, directors and consultants of the Company or any subsidiaries. This plan became effective as of September 3, 2005 after the Company had completed a one for twenty reverse split.

		On October 1, 2006, the Company granted to a marketing consultant 25,000 options to purchase the Company’s common stock at a price of $1.80 per share. These options vested immediately upon grant and are exercisable for a period of five years. The Company valued the foregoing options using the Black Scholes option pricing model using the following assumptions: no dividend yield; expected volatility rate of 91.58%; risk free interest rate of 5% and an average life of 5 years resulting in a value of $1.298 per option granted.

		On September 14, 2006, pursuant to an S-8 filed with the SEC, the Company registered 1,150,000 common shares, pursuant to compensation arrangements.

		On August 17, 2007, pursuant to the terms of the Company’s 2004 Plan, the Company granted to an employee 100,000 options to purchase the Company’s common stock at a price of $1.50 per share. These options will vest over the next 3 years and are exercisable for a period of 5 years. The Company valued the foregoing options using the Black Scholes option pricing model using the following assumptions: no dividend yield; expected volatility rate of 115%; risk free interest rate of 4.75% and an average life of 5 years resulting in a value of $1.24 per option granted. The value of these options will be recognized on a straight-line basis over the next three years and accordingly a value of $17,381 has been recorded in the period ended December 31, 2007.

		On September 21, 2007 the Company granted to employees and directors a total of 570,000 options to purchase the Company’s common stock at a price of $1.75 per share. These options will vest over the next 3 years and are exercisable for a period of 10 years. The Company valued the foregoing options using the Black Scholes option pricing model using the following assumptions: no dividend yield; expected volatility rate of 115%; risk free interest rate of 4.75% and an average life of 7 years resulting in a value of $1.47 per option granted. The value of these options will be recognized on a straight-line basis over the next three years and accordingly a value of $83,889 has been recorded in the period ended December 31, 2007.

		A summary of the option activity for the nine months ended December 31, 2007 pursuant to the terms of the plans is as follows:


	2001 Plan				2004 Plan				Other
			Weighted				Weighted				Weighted
	Outstanding		Average		Outstanding		Average		Outstanding		Average
	Options		Exercise Price		Options		Exercise Price		Options		Exercise Price
Options outstanding , March 31, 2007		222,500	$	1.29		210,666	$	3.19		—		—

Granted		—		—		520,000		1.71		150,000	$	1.75
Exercised		—		—		—		—		—		—
Cancelled or expired		—		—		—		—		—		—

Options outstanding, December 31, 2007		222,500	$	1.29		730,666	$	2.29		150,000	$	1.75

Options exercisable December 31, 2007		222,500	$	1.29		210,666	$	4.46		—		—

Exercise price range	$	1.00 to $4.00			$	1.50 to $4.00			$	1.75

Weighted average remaining life	4.3 years				5.62 years				8.97 years

Shares available for future issuance		27,500				69,334				N/A

A summary of the Company’s equity compensation plans approved and not approved by shareholders is as follows:

Number of

Number of securities

securities to be

remaining available for

issued upon

future issuance under

exercise of

Weighted-average

equity compensation

of outstanding

exercise price of

plans (excluding

options, warrants

outstanding options

securities reflected

Plan Category

and right

warrants and rights

in column (a))

Equity Compensation Plans approved by security holders

1,103,166

2.01

96,834

Equity Compensation Plans not approved by security holders

297,298

1.50

1,400,464

1.91

96,834

Prior to January 1, 2006, the Company accounted for employee stock-based compensation under the recognition and measurement principles of Accounting Principles Board Opinion (“APB”) No. 25, “Accounting for Stock Issued to Employees,” and related Interpretations, as permitted by SFAS No. 123, “Accounting for Stock-Based Compensation”. Under the recognition principles of APB No. 25, compensation expense related to restricted stock and performance units was recognized in the financial statements. However, APB No. 25 generally did not require the recognition of compensation expense for stock options because the exercise price of these instruments was generally equal to the fair value of the underlying common stock on the date of grant, and the related number of shares granted were fixed at that point in time.

		Effective January 1, 2006, the Company adopted the fair value recognition provisions of SFAS No. 123(R), “Share-Based Payment”. In addition to recognizing compensation expense related to restricted stock and performance units, SFAS No. 123(R) also requires recognition of compensation expense related to the estimated fair value of stock options. The Company adopted SFAS No. 123(R) using the modified-prospective-transition method. Under that transition method, compensation expense recognized subsequent to adoption includes: (a) compensation cost for all share-based payments granted prior to, but not yet vested as of January 1, 2006, based on the values estimated in accordance with the original provisions of SFAS No. 123, and (b) compensation cost for all share-based payments granted subsequent to January 1, 2006, based on the grant-date fair values estimated in accordance with the provisions of SFAS No. 123(R). Consistent with the modified-prospective-transition method, the Company’s results of operations for prior periods have not been adjusted to reflect the adoption of FAS 123(R). For the nine months) ended December 31, 2007 the Company recognized $101,270 (2006 — $221,959) in compensation expense in the consolidated statement of operations.

17.		COMMON STOCK WARRANTS AND OTHER OPTIONS

		On February 10, 2006, the Company issued to an individual the right to purchase 150,000 shares of the Company’s common stock at an exercise price of $2.60 per share for a term of five (5) years pursuant to the terms and conditions of a Stock Option Agreement as consideration for past services performed and the release of any and all claims under this individual’s prior agreements with the Company. The 150,000 options have been valued in accordance with the Black-Scholes pricing model utilizing an historic volatility factor of 1.55, a risk free interest rate of 4.5% and an expected life for the options of five years, resulting in a value of $2.41 per option granted for a total for the warrants of $361,500. The value of this option grant was recorded as of December 31, 2005 as a research and development expense.

		In November 2006, the Company entered into a Settlement Agreement and Release (“Settlement Agreement”) with this individual pursuant to which the prior agreement was terminated. In connection with the Settlement Agreement, the Company agreed to pay this individual $65,000 in settlement of all accounts which was recorded as an expense as of the date of the Settlement Agreement and he in turn agreed to the cancellation of his options to purchase 150,000 shares of the Company’s common stock in exchange for certain product rights that the Company had elected not to pursue.

		As of December 31, 2007, the Company has 7,260,026 warrants to purchase the Company’s common stock outstanding that were not granted under shareholder approved equity compensation plans at prices ranging between $1.20 and $3.00 per share with expiration dates between August 2007 and September 2012 as follows:


				Weighted
	Outstanding			Average Exercise
	Warrants			Price
Warrants and options outstanding , March 31, 2007		3,105,651		$	1.72
Granted		4,200,000			1.55
Exercised		(10,000	)		1.59
Cancelled or expired		(35,725	)		—

Warrants exercisable December 31, 2007		7,260,026		$	1.67

Exercise price range	$	1.20 to $10.00

Weighted average remaining life	4.95 Years

18.		SEGMENT INFORMATION

		The Company’s only operating segment consists of dental products and oral hygiene products sold by Remedent Inc., Remedent N.V., Sylphar N.V., and Remedent Asia. Since the Company only has one segment, no further segment information is presented.


	December 31, 2007		December 31, 2006
U.S. sales	$	316,208	$	173,733
Foreign sales		4,137,691		4,696,428

	$	4,453,899	$	4,870,161

19.		COMMITMENTS AND CONTINGENCIES

		Real Estate Lease

		The Company leases its 26,915 square feet office and warehouse facility in Deurle, Belgium from an unrelated party pursuant to a nine year lease commencing December 20, 2001 at a base rent of $6,838 per month ($9,696 per month at December 31, 2007). In addition, the Company is responsible for the payment of annual real estate taxes for the property which totaled €3,245 ($4,382) for calendar year 2006. The minimum aggregate rent to be paid over the remaining lease term based upon the conversion rate for the € at December 31, 2007 is $283,142. Rent expense for the foregoing lease for the nine months ended December 31, 2007 and December 31, 2006 was $80,991 and $59,040 respectively.

		Minimum monthly lease payments for real estate, and all other leased equipment for the next four years are as follows based upon the conversion rate for the (Euro) at December 31, 2007.


March 31, 2008	$	231,425
March 31, 2009	$	212,805
March 31, 2010	$	68,954
March 31, 2011	$	37,790

Item 2. Management’s Discussion and Analysis of Financial Condition or Plan of Operations

The discussion contained herein is for the nine months ended December 31, 2007 and 2006. The following discussion should be read in conjunction with the Company’s condensed consolidated financial statements and the notes to the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-QSB for the quarterly period ended December 31, 2007. In addition to historical information, this section contains “forward-looking” statements, including statements regarding the growth of product lines, optimism regarding the business, expanding sales and other statements. Words such as expects, anticipates, intends, believes, sees, estimates and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks and uncertainties that are difficult to predict. Actual results could vary materially from the description contained herein due to many factors including continued market acceptance of our products. In addition, actual results could vary materially based on changes or slower growth in the oral care and cosmetic dentistry products market; the potential inability to realize expected benefits and synergies; domestic and international business and economic conditions; changes in the dental industry; unexpected difficulties in penetrating the oral care and cosmetic dentistry products market; changes in customer demand or ordering patterns; changes in the competitive environment including pricing pressures or technological changes; technological advances; shortages of manufacturing capacity; future production variables impacting excess inventory and other risk factors. Factors that could cause or contribute to any differences are discussed in “Risk Factors” and elsewhere in the Company’s annual report on Form 10-KSB filed on July 13, 2007 with the Securities and Exchange Commission. Except as required by applicable law or regulation, the Company undertakes no obligation to revise or update any forward-looking statements contained in this Quarterly Report on Form 10-QSB for the quarterly period ended December 31, 2007. The information contained in this Quarterly Report on Form 10-QSB for the quarterly period ended December 31, 2007 is not a complete description of the Company’s business or the risks associated with an investment in the Company’s common stock. Each reader should carefully review and consider the various disclosures made by the Company in this Quarterly Report on Form 10-QSB for the quarterly period ended December 31, 2007 and in the Company’s other filings with the Securities and Exchange Commission.

Overview

We design, develop, manufacture and distribute cosmetic dentistry products. Leveraging our knowledge of regulatory requirements regarding dental products and management’s experience in the needs of the professional dental community, we have developed a family of teeth whitening products for both professional and “Over-The-Counter” use, that are distributed in Europe, Asia and the United States. We manufacture many of our products in our facility in Deurle, Belgium as well as outsourced manufacturing in China. We distribute our products using both our own internal sales force and through the use of third party distributors. As a result of this approach, we have established dealers in 35 countries encompassing, Europe, Asia, Latin America, the Pacific Rim and the Middle East.

For the fiscal years ending March 31, 2003 through 2007, substantially all of our revenue has been generated by our Belgian subsidiary, Remedent N.V., which has experienced substantial growth in its revenues.

Our products can be generally classified into the following categories: professional dental products and “Over-The Counter” tooth whitening products. In the fall of 2006, we launched a proprietary veneer technology product line called GlamSmile™. GlamSmile

veneers are ultra thin claddings made from a mixture of a hybrid composite and porcelain materials which are attached to the front of the patient’s teeth. Because GlamSmile veneers are so thin, the dentist does not need to remove healthy tooth structure leaving the patient’s healthy tooth structure intact which results in several important benefits: (i) no local anesthesia is required to prepare the teeth; (ii) reduced (if any) tooth sensitivity post-procedure; and (iii) the process is reversible. In addition, in the three months ended March 31, 2006, a variation of our MetaTray^® product named iWhite^® was introduced to our global retail distribution network. We introduced MetaTray in August 2005, our next generation of products targeted for the professional dentist market. MetaTray is a completely self-contained whitening system that can be administered by dentists.

During the second half of the fiscal year ended March 31, 2006, we established sales offices in Singapore to service the Asian market. In conjunction with the establishment of the office in Singapore, we formed a wholly owned subsidiary, Remedent Asia Pte Ltd. Although sales in Singapore have taken time to materialize, we believe progress is being made in establishing market share in this region.

In June 2007, we completed a private placement of 5,600,000 shares of our common stock at $1.25 per share and warrants to purchase up to 4,200,000 shares of common stock at an exercise price of $1.55 per share to certain institutional and accredited investors for an aggregate purchase price of $7,000,000, of which we received proceeds of approximately $5,776,993, net of costs.

The following table presents our consolidated statements of loss, as a percentage of sales, for the periods indicated.


	For the three months ended						For the nine months ended
	December 31,						December 31,
	2007			2006			2007			2006
NET SALES		100.00	%		100.00	%		100.00	%		100.00	%
COST OF SALES		58.20	%		57.96	%		58.23	%		53.96	%

GROSS PROFIT		41.80	%		42.04	%		41.77	%		46.04	%

OPERATING EXPENSES
Research and development		8.07	%		5.47	%		5.56	%		6.24	%
Sales and marketing		28.65	%		10.33	%		22.38	%		15.26	%
General and administrative		50.98	%		75.21	%		64.91	%		52.22	%
Depreciation and amortization		3.76	%		5.17	%		4.85	%		3.03	%

TOTAL OPERATING EXPENSES		91.46	%		96.18	%		97.70	%		76.75	%

LOSS FROM OPERATIONS		(49.66	)%		(54.14	)%		(55.93	)%		(30.71	)%

Other income (expense)		(0.35	)%		(1.71	)%		0.65	%		0.67	%

LOSS BEFORE INCOME TAXES		(50.01	)%		(55.85	)%		(55.28	)%		(30.04	)%

NET INCOME (LOSS)		(50.01	)%		(55.85	)%		(55.28	)%		(30.04	)%

Net Sales

Net sales increased for the three months ended December 31, 2007 by $973,542, or 84%, to $2,132,950 compared to $1,159,408 for the three months ended December 31, 2006. For the three months ended December 31, 2007, the increase in sales is primarily due to the increased sales of OTC products, more specifically the iWhite and Remesense product lines as well as increased sales of GlamSmile veneers.

Net sales of the veneer product, GlamSmile, increased for the three months ended December 31, 2007 by $284,068, or 3,222.19 % to $292,884 compared to $8,816 for the three months ended December 31, 2006.

For the nine months ended December 31, 2007, sales decreased by $416,262 to $4,453,899 as compared to $4,870,161 for the nine months ended December 31, 2006. The decrease in net sales for the nine months ended December 2007 as compared to the net sales for the nine months ended December 2006 is primarily due to the non- recurrence of one specific iWhite launch order in the summer of 2006.

Net sales of the veneer product, GlamSmile, increased for the nine months ended December 31, 2007 by $483,244, or 3,277.56 % to $497,988, compared to $14,744 for the nine months ended December 31, 2006.

Cost of Sales

Cost of sales increased for the three months ended December 31, 2007 by $599,380, or 84.7% to $1,271,430 as compared to $672,050 for the three months ended December 31, 2006. The increase in cost of sales is in line with the increase in sales of 84% which is as discussed above.

For the nine months ended December 31, 2007, cost of sales decreased by $4,218 from $2,627,724 for the nine months ended December 31, 2006 to $2,623,506 for the nine months ended December 31, 2007. This decrease is primarily the result of the decreased sales volume for the period. Cost of sales as a percentage of net sales increased 4% from 53.96% for the nine months ended December 31, 2006 to 58% for the nine months ended December 31, 2007 primarily for the same reasons discussed above for the three month period.

Gross Profit

Gross profit increased by $374,162 to $861,520 for the three month period ended December 31, 2007 as compared to $487,358 for the three month period ended December 31, 2006. This increase is the result of the increased sales as explained above. For the three month period ended December 31, 2007, our gross profit as a percentage of sales decreased 1.65% from 42.04% to 40.39% as compared to the three months ended December 2006. This decrease in percentage gross profit is mostly due to the mix in the product range, some products have higher margins than others, which is reflected in the decreased gross profit for the three month period ended December 31, 2007 compared to December 31, 2006.

For the nine months ended December 31, 2007, gross profit decreased by $412,044 to $1,830,393 as compared to $2,242,437 for the nine months ended December 31, 2006. The decrease for the nine month period is primarily due to the decreased sales for the nine months ended December 31, 2007 as compared to the nine months ended December 31, 2006.

Operating Expenses

Research and Development.

Research and development expenses increased by 108,714, or 171.5%, to $172,108 for the three months ended December 31, 2007 as compared to $63,394 for the three months ended December 31, 2006. The increase is due to product tests and upscale costs for a new consumer product, based on dissolvable strip technology, as well as line extensions for the Glamsmile veneers.

For the nine months ended December 31, 2007, research and development expenses decreased $56,229 or 18.5%, to $247,665 as compared to $303,894 for the nine months ended December 31, 2006. The decrease is the result of the termination of the consultancy agreement in reference to the Meta Tray and IWhite products at the end of December 31, 2006 as well as other research and development costs associated with the launch of the Meta Tray and iWhite products, which did not recur.

Sales and marketing costs

Sales and marketing costs increased $491,388, or 410.3%, to $611,144 for the three months ended December 31, 2007 as compared to $119,756 for the three months ended December 31, 2006. The increase is partially due to the set up of a US office in order to support the introduction of our veneer product into the US market. This office incurred additional sales and marketing costs of $179,370 for the three month period ended December 31, 2007. Also, the sales and marketing costs for our US OTC division increased by $30,547 compared to the three months ended December 31, 2006 as additional sales force was deployed. It should also be noted that the sales and marketing costs for the three months ended December 31, 2006, were low due to a reorganization that was finalized at the end of September 30, 2006.

For the nine months ended December 31, 2007, sales and marketing costs increased $253,767, or 34.1%, to $996,937 as compared to $743,170 for the nine months ended December 31, 2006. The increase is largely due to the set up of a US office to support our veneer product in the US market as discussed above for the three month period.

General and administrative costs

General and administrative costs for the three months ended December 31, 2007 and 2006 were $1,087,313 and $872,042, respectively, representing an increase of $215,271 or 24.7%. The increase in general and administrative costs for the three months ended December 31, 2007 as compared to the prior year is the result of our investments made to increase customer support concurrent with the launch of our GlamSmile veneers product line in both Europe and the US.

For the nine months ended December 31, 2007, general and administrative costs increased $348,011, or 13.7%, to $2,891,165 as compared to $2,543,154 for the nine months ended December 31, 2006. The foregoing increase is primarily due to the result of the three month increase discussed above.

Depreciation and amortization

Our depreciation and amortization expense increased from $59,896 to $80,157 for the three months ended December 31, 2007 compared to the three months ended December 31, 2006, an increase of 33.8%. This increase is due to investments we have made in updating and modernizing our Dental Lab and related machinery, in order to bring it to a higher professional level. With the described investments made, our lab now has the capacity to provide a higher level of support for our sales team, especially with respect to the support of our veneers.

For the nine months ended December 31, 2007, depreciation and amortization costs increased $68,351, or 46.3%, to $215,941 as compared to $147,590 for the nine months ended December 31, 2006. The foregoing increase is the result of depreciation expense associated with additional infrastructure investments and investments in a semi-automatic production machine which allows higher production capacity at lower production cost and additional investments made as explained above.

Net interest expense

Net interest expense decreased by $8,261 to $16,588 from $24,849 during the three months ended December 31, 2007 over the comparable three months ended December 31, 2006. The decrease is mainly the result of decreased utilization of our bank credit facility. For the three months ended December 31, 2007 the Company earned $9,040 in interest revenue as compared to $nil for the three months ended December 31, 2006. Interest was earned on cash balances received as a result of the Company’s 2007 private placement.

For the nine months ended December 31, 2007, interest expense decreased $50,516 to $71,802 as compared to $122,318 for the nine months ended December 31, 2006. The main reason is the decreased use of our available bank credit facility which occurred primarily because of the Company’s decision to reduce the use of the credit line with funds received pursuant to the recent private placement. For the nine months ended December 31, 2007 the Company earned $100,665 in interest revenue as compared to $nil for the nine months ended December 31, 2006. Interest income was earned because of cash balances on hand as a result of the Company’s 2007 equity financings.

Liquidity and Capital Resources

We believe we have sufficient cash and available cash resources to meet our capital expenditures and continue our operations for the next twelve months. However, we anticipate that we may require additional financing to expand our product line and customer base, and establish operations in markets other than Europe. We intend to obtain the additional capital required for expansion by obtaining debt or through the sale of our equity securities. Such financings may result in further dilution in the equity ownership of our shares. There is still no assurance that we will be able to maintain operations at a level sufficient for an investor to obtain a return on his investment in our common stock. Further, we may continue to be unprofitable.

Cash and Cash equivalents

Our balance sheet at December 31, 2007 reflects cash and cash equivalents of $2,016,538 as compared to $126,966 as of March 31, 2007, an increase of $1,889,572. The increase of cash and cash equivalents is due to the completion of the Private Placement which was finalized at the end of the quarter ending June 30, 2007.

Operations

Net cash used by operations increased by $1,312,775 resulting in net cash being used by operations of $2,150,267 for the nine months ended December 31, 2007 as compared to net cash used by operations of $837,492 for the nine months ended December 31, 2006. The increase in net cash used by operations for the nine months ended December 31, 2007 as compared to the nine months ended December 31, 2006 is primarily attributable to the net loss. Cash used by our net loss for the nine months ended December 31, 2007 was offset by a reduction in our accounts receivable of $137,273 and an increase in our accounts payable of $203,075.

Investing activities

Net cash used in investing activities totaled $852,193 for the nine months ended December 31, 2007 as compared to net cash used in investing activities of $285,574 for the nine months ended December 31, 2006. The increase in net cash used in investing activities for the nine months ended December 31, 2007 is primarily attributable to purchases of equipment for $165,195 and investments of $675,000 made with respect to our GlamSmile division.

Financing activities

Net cash provided by financing activities totaled $5,044,277 for the nine months ended December 31, 2007 as compared to net cash provided in financing activities of $1,137,460 for the nine months ended December 31, 2006. The increase in net cash provided from financing activities in the nine months period ended December 31, 2007 is primarily attributable to the net cash proceeds received by the Company from a Private Placement, which took place at the end of the quarter ended June 30, 2007, with net proceeds totaling $5,776,993 which was offset by a $825,978 repayment of our existing Credit Line.

During the three months ended December 31, 2007 the Company also received $15,900 on the exercise of 10,000 common stock purchase warrants.

Off-balance Sheet Arrangements

At December 31, 2007, we did not have any transactions, obligations or relationships that could be considered off-balance sheet arrangements.

Recently Issued Accounting Standards

Effective January 1, 2007, we adopted the provisions of the FASB Staff Position (“FSP”) on EITF Issue 00-19-2 “Accounting for Registration Payment Arrangements”. This accounting position was adopted on a prospective basis with no restatement of prior period consolidated financial statements. This position specifies that the contingent obligation to make future payments or otherwise transfer consideration under a registration payment arrangement, whether issued as a separate agreement or included as a provision of a financial instrument or other agreement, should be separately recognized and measured in accordance with FASB Statement No. 5 “Accounting for Contingencies”. Transition to the FSP will be achieved by reporting a change in accounting principle through a cumulative-effect adjustment to the opening balance of deficit.

We adopted FASB Interpretation No.48, “Accounting for Uncertainty in Income Taxes, an interpretation of FASB Statements No. 109” (“FIN 48”) on January 1, 2007. FIN 48 clarifies the accounting for uncertainty in income taxes by prescribing a two-step method of first evaluating whether a tax position has met a more likely than not recognition threshold and second, measuring that tax position to determine the amount of benefit to be recognized in the financial statements. FIN 48 provides guidance on the presentation of such positions within a classified statement of financial position as well as on derecognition, interest and penalties, accounting in interim periods, disclosure, and transition. The adoption of this statement did not have a material effect on our company’s interim unaudited consolidated financial statements.

Item 3. Controls and Procedures.

(a) Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports filed or submitted by the Company under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the Securities and Exchange Commission. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports filed under the Securities Exchange Act of 1934 is accumulated and communicated to the Company’s management, including its principal executive and financial officers, as appropriate, to allow timely decisions regarding required disclosure.

The Company carried out an evaluation, under the supervision and with the participation of its management, including its principal executive officer and principal financial officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of the end of the period covered by this report. Based upon and as of the date of that evaluation, the Company’s principal executive officer and financial officers concluded that the Company’s disclosure controls and procedures are effective to

ensure that information required to be disclosed in the reports the Company files and submits under the Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.

(b) Changes in Internal Controls

There were no changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2007 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 2. Unregistered Sale of Equity Securities.

None.

Item 3. Defaults In Senior Securities.

None.

Item 4. Submission Of Matters To A Vote Of Security Holders.

The annual meeting of shareholders of the Company was held on November 5, 2007. The shareholders voted, either in person or by proxy, on the following proposals. The directors listed below were elected, and all other proposals submitted to a vote of the shareholders were approved, with the results of the shareholder vote as follows:

The following four directors were elected to hold office for one-year terms or until their successors are elected and qualified:


			Votes Against
	Votes For		or Withheld		Total Voted
Guy De Vreese		16,783,357		2,657		16,786,014
Robin List		16,783,357		2,657		16,786,014
Stephen Ross		16,784,325		721		16,785,046
Fred Kolsteeg		16,784,325		721		16,785,046

To approve adoption of the 2007 Equity Incentive Plan:


For			15,719,684
Against			23,410
Abstain			1,500

To ratify the Board of Directors appointment of PKF Bedrijfsrevisoren as the Company’s independent registered accounting firm for the 2008 fiscal year.


For			16,780,168
Against			2,002
Abstain			2,810

Item 5. Other Information.

None.


	For the three months ended						For the nine months ended
	December 31,						December 31,
	(Unaudited)						(Unaudited)
	2007			2006			2007			2006
Net Income (Loss)	$	(1,096,750	)	$	(647,563	)	$	(2,492,452	)	$	(1,585,151	)
OTHER COMPREHENSIVE INCOME (LOSS):
Foreign currency translation adjustment		58,949			31,096			10,345			56,511

Comprehensive income (loss)	$	(1,037,801	)	$	(616,467	)	$	(2,482,107	)	$	(1,528,640	)


31.1		Certifications of the Chief Executive Officer Under Section 302 of the Sarbanes-Oxley Act

31.2		Certifications of Chief Financial Officer Under Section 302 of the Sarbanes-Oxley Act

32.1		Certifications of the Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act

32.2		Certifications of the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act


		REMEDENT, INC.
Dated: February 13, 2008		/s/ Robin List

		By: Robin List
		Its: Chief Executive Officer (Principal Executive Officer) and Director

Dated: February 13, 2008		/s/ Philippe Van Acker

		By: Philippe Van Acker
		Its: Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

31.1		Certifications of the Chief Executive Officer Under Section 302 of the Sarbanes-Oxley Act

31.2		Certifications of Chief Financial Officer Under Section 302 of the Sarbanes-Oxley Act

32.1		Certifications of the Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act

32.2		Certifications of the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents


	Page
PART I — FINANCIAL INFORMATION		3
Item 1. Interim Consolidated Financial Statements		3
Condensed Consolidated Balance Sheet as of December 31, 2007 (Unaudited) and March 31, 2007		3
Condensed Consolidated Statements of Operations for the Three and Nine months ended December 31, 2007 and December 31, 2006 (Unaudited)		4
Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Nine months Ended December 31, 2007 and December 31, 2006 (Unaudited)		5
Condensed Consolidated Statements of Cash Flows for the Nine months Ended December 31, 2007 and December 31, 2006 (Unaudited)		6
Notes to Interim Condensed Consolidated Financial Statements (Unaudited)		8
Item 2. Management’s Discussion and Analysis or Plan of Operation		17
Item 3. Controls and Procedures		21
PART II — OTHER INFORMATION		22
Item 1. Legal Proceedings		22
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		22
Item 3. Defaults upon Senior Securities		22
Item 4. Submission of Matters to Vote of Security Holders		22
Item 5. Other Information		22
Item 6. Exhibits		23
Signatures		24